Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05323292

Vitamin A Status in Patients With Vocal Fold Leukoplakia

This study will determine systemic vitamin A status and lesion histopathology of participants with vocal fold hyperkeratosis resulting in clinical leukoplakia.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Wisconsin Hospitals and Clinics

Madison, Wisconsin, 53792, United States

About this study

The investigator's overarching goal is to determine if there is a pathophysiologic rationale for vitamin A supplementation in the treatment of vocal fold hyperkeratosis. Vocal fold hyperkeratosis is an accumulation of epithelial surface keratin resulting in clinical leukoplakia. It is primarily managed using destructive techniques that risk iatrogenic injury, fibrosis, and voice impairment. Given the potential morbidity of biopsy and lesion removal, there is a need for new approaches to the prevention and treatment of vocal fold leukoplakic disorders that are non-destructive. Vitamin A is a key regulator of epithelial health and systemic vitamin A deficiency could directly contribute to hyperkeratosis. Based on vitamin A's importance to vocal fold stellate and epithelial cell biology and its direct relevance to vocal fold hyperkeratosis, this study will assess vitamin A status in participants with vocal fold hyperkeratosis. An association would suggest further study on the effects of vitamin A optimization and/or supplementation in patients with leukoplakia, as well as an adjuvant therapy in participants for whom surgical treatment is indicated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing to provide informed consent.
  • Willing to comply with all study procedures and be available for the duration of the study.
  • Ability to take oral medication.
  • At least 18 years of age.
  • Leukoplakia study groups:
  • Leukoplakia due to hyperkeratosis with dysplasia: biopsy-confirmed diagnosis of hyperkeratosis with dysplasia.
  • Leukoplakia due to hyperkeratosis with no dysplasia: biopsy-confirmed diagnosis of hyperkeratosis with no dysplasia.
  • Control group: Laryngoscopy showing no evidence of vocal fold epithelial disease.

Exclusion criteria

  • History of malignant vocal fold epithelial pathology.
  • History of metabolic or liver disorder.
  • History of anorexia or bulimia.
  • Pregnant, lactating, or planning on becoming pregnant during the study period.
  • History of >4.5 kg weight loss in the past 90 days.
  • Medical or other inability to complete an 8 hour fast.
  • Acute respiratory or gastrointestinal illness.
  • Currently incarcerated.
  • Impaired decision-making capacity.
  • No or limited English speaking ability; illiterate or low-literacy ability.
  • Profound visual or hearing impairment that limits written or verbal communication.
  • Status relationship with a member of the study team.
  • Not suitable for study participation due to other reasons at the discretion of the investigators.

Treatment and study plan

Primary outcomes

  1. Vitamin A liver reserves

    Time frame: 14 days

    Total vitamin A liver concentration determined using retinol stable isotope dilution (μmol/g)

Secondary outcomes

  1. Serum retinol

    Time frame: Baseline

    Serum retinol concentration (μmol/L)

  2. Serum retinyl esters

    Time frame: Baseline

    Serum retinyl esters concentration (μmol/L)

  3. Serum carotenoids

    Time frame: Baseline

    Serum carotenoid concentrations (μmol/L)

Sponsors and collaborators

Lead sponsor

University of Wisconsin, Madison

Other

Collaborators

  • National Institute on Deafness and Other Communication Disorders (NIDCD)

Registry information

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Apr 12, 2022
Registry last updated
Jul 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.